NEW YORK, Jan. 19, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Identiv, Inc. (Nasdaq:INVE) securities between November 7, 2013 and November 23, 2015.
Click here to learn about the case: http://docs.wongesq.com/INVE-Info-Request-Form-1042. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Identiv had engaged in inappropriate revenue recognition practices; (2) Identiv’s senior management encouraged a closed and ineffective control environment; (3) Identiv’s key accounting metrics were misstated; and (4) Identiv lacked adequate internal controls at all relevant times.
If you suffered a loss in Identiv you have until February 5, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/INVE-Info-Request-Form-1042.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]


Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Anta Sports Expands Global Footprint With Strategic Puma Stake
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Washington Post Publisher Will Lewis Steps Down After Layoffs
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 



